BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A, Furuya T, Tangoku A, Oka M, Sasaki K. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 2004;17:617-22. [DOI: 10.1038/modpathol.3800107] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Panera N, Crudele A, Romito I, Gnani D, Alisi A. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci 2017;18:E99. [PMID: 28067792 DOI: 10.3390/ijms18010099] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
2 Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-687. [PMID: 16929323 DOI: 10.1038/nrc1934] [Cited by in Crossref: 1337] [Cited by in F6Publishing: 1312] [Article Influence: 83.6] [Reference Citation Analysis]
3 Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142:164-175. [PMID: 24333502 DOI: 10.1016/j.pharmthera.2013.12.004] [Cited by in Crossref: 416] [Cited by in F6Publishing: 414] [Article Influence: 46.2] [Reference Citation Analysis]
4 Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL. Telomerase Deletion Limits Progression of p53-Mutant Hepatocellular Carcinoma With Short Telomeres in Chronic Liver Disease. Gastroenterology 2007;132:1465-75. [DOI: 10.1053/j.gastro.2007.01.045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
5 Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis. 2015;19:261-276. [PMID: 25921662 DOI: 10.1016/j.cld.2015.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
6 Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS, Kwon MS, Fiegler H, Carter NP, Rhyu MG, Chung YJ. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 2008;123:2808-2815. [PMID: 18803288 DOI: 10.1002/ijc.23901] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
7 Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways: Cell death and hepatocarcinogenesis. Journal of Gastroenterology and Hepatology 2011;26:213-9. [DOI: 10.1111/j.1440-1746.2010.06582.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 7.4] [Reference Citation Analysis]
8 Baik S, Jee B, Choi J, Yoon H, Lee K, Kim Y, Lim Y. DNA profiling by array comparative genomic hybridization (CGH) of peripheral blood mononuclear cells (PBMC) and tumor tissue cell in non-small cell lung cancer (NSCLC). Mol Biol Rep 2009;36:1767-78. [DOI: 10.1007/s11033-008-9380-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
9 Welte S, Urbanik T, Elßner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma. PLoS One 2014;9:e110591. [PMID: 25329885 DOI: 10.1371/journal.pone.0110591] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lau SH, Guan XY. Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin 2005;26:659-65. [PMID: 15916730 DOI: 10.1111/j.1745-7254.2005.00126.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
11 Kim H, Kim K, Yu SJ, Jang ES, Yu J, Cho G, Yoon JH, Kim Y. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring. PLoS One 2013;8:e63468. [PMID: 23717429 DOI: 10.1371/journal.pone.0063468] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
12 Cariati F, Borrillo F, Shankar V, Nunziato M, D'Argenio V, Tomaiuolo R. Dissecting Intra-Tumor Heterogeneity by the Analysis of Copy Number Variations in Single Cells: The Neuroblastoma Case Study. Int J Mol Sci 2019;20:E893. [PMID: 30791380 DOI: 10.3390/ijms20040893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006;6:776-88. [PMID: 16990855 DOI: 10.1038/nrc1994] [Cited by in Crossref: 271] [Cited by in F6Publishing: 271] [Article Influence: 16.9] [Reference Citation Analysis]
14 Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008;27:2097-108. [PMID: 17934521 DOI: 10.1038/sj.onc.1210848] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
15 Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, Wilkens L, Destro A, Fiamengo B, Manns MP, Roncalli M, Rudolph KL. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007;45:968-76. [PMID: 17393506 DOI: 10.1002/hep.21552] [Cited by in Crossref: 112] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
16 Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 2013;13:234-44. [PMID: 23297823 DOI: 10.2174/1568009611313030002] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 13.2] [Reference Citation Analysis]
17 Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006;125:665-677. [PMID: 16713561 DOI: 10.1016/j.cell.2006.03.041] [Cited by in Crossref: 360] [Cited by in F6Publishing: 345] [Article Influence: 22.5] [Reference Citation Analysis]
18 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
19 Qi LN, Li LQ, Chen YY, Chen ZH, Bai T, Xiang BD, Qin X, Xiao KY, Peng MH, Liu ZM. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China. PLoS One. 2013;8:e83465. [PMID: 24391771 DOI: 10.1371/journal.pone.0083465] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
20 Tauriello DV, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H, Maurice MM. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 2010;37:607-619. [PMID: 20227366 DOI: 10.1016/j.molcel.2010.01.035] [Cited by in Crossref: 148] [Cited by in F6Publishing: 130] [Article Influence: 12.3] [Reference Citation Analysis]
21 Huang D, Du C, Ji D, Xi J, Gu J. Overexpression of LAMC2 predicts poor prognosis in colorectal cancer patients and promotes cancer cell proliferation, migration, and invasion. Tumour Biol 2017;39:101042831770584. [DOI: 10.1177/1010428317705849] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
22 Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics. 2008;5:45-60. [PMID: 18282123 DOI: 10.1586/14789450.5.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
23 Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, Makuuchi M, Aburatani H. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene. 2006;25:5581-5590. [PMID: 16785998 DOI: 10.1038/sj.onc.1209537] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
24 Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int 2013;2013:915636. [PMID: 24303503 DOI: 10.1155/2013/915636] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
25 Zhou P, Hao Z, Wang X, Gao J, Li D, Xie S, Zhang TC. UV Irradiation Triggers Cylindromatosis Translocation, Modification, and Degradation in a Proteasome-Independent Manner. DNA Cell Biol 2016;35:140-5. [PMID: 26717101 DOI: 10.1089/dna.2015.3061] [Reference Citation Analysis]
26 Takiuchi D, Eguchi H, Nagano H, Iwagami Y, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Mori M, Doki Y. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 2013;13:517-23. [DOI: 10.1016/j.pan.2013.06.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
27 Daisuke H, Kato H, Fukumura K, Mayeda A, Miyagi Y, Seiki M, Koshikawa N. Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma. Cancer Sci 2021. [PMID: 34689384 DOI: 10.1111/cas.15149] [Reference Citation Analysis]
28 Steinemann D, Skawran B, Becker T, Tauscher M, Weigmann A, Wingen L, Tauscher S, Hinrichsen T, Hertz S, Flemming P, Flik J, Wiese B, Kreipe H, Lichter P, Schlegelberger B, Wilkens L. Assessment of differentiation and progression of hepatic tumors using array-based comparative genomic hybridization. Clin Gastroenterol Hepatol. 2006;4:1283-1291. [PMID: 16979954 DOI: 10.1016/j.cgh.2006.07.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
29 Xu C, He X, Zheng Z, Zhang Z, Wei C, Guan K, Hou L, Zhang B, Zhu L, Cao Y, Zhang Y, Cao Y, Ma S, Wang P, Zhang P, Xu Q, Ling Y, Yang X, Zhong H. Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response. J Virol 2014;88:11356-68. [PMID: 25056901 DOI: 10.1128/JVI.01400-14] [Cited by in Crossref: 55] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
30 Wu W, Zhu H, Fu Y, Shen W, Xu J, Miao K, Hong M, Xu W, Liu P, Li J. Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia. Leuk Lymphoma 2014;55:588-94. [PMID: 23725390 DOI: 10.3109/10428194.2013.809077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
31 Kanamori M, Sano A, Yasuda T, Hori T, Suzuki K. Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. J Exp Clin Cancer Res 2012;31:100. [PMID: 23199169 DOI: 10.1186/1756-9966-31-100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
32 Garg M, Braunstein G, Koeffler HP. LAMC2 as a therapeutic target for cancers. Expert Opin Ther Targets 2014;18:979-82. [PMID: 24976367 DOI: 10.1517/14728222.2014.934814] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
33 Alameda JP, Moreno-Maldonado R, Navarro M, Bravo A, Ramírez A, Page A, Jorcano JL, Fernández-Aceñero MJ, Casanova ML. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene 2010;29:6522-32. [PMID: 20838385 DOI: 10.1038/onc.2010.378] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
34 Peychal SE, Bilger A, Pitot HC, Drinkwater NR. Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17. Carcinogenesis 2009;30:879-85. [PMID: 19255062 DOI: 10.1093/carcin/bgp054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
35 Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010;17:25-34. [PMID: 19373246 DOI: 10.1038/cdd.2009.43] [Cited by in Crossref: 252] [Cited by in F6Publishing: 247] [Article Influence: 21.0] [Reference Citation Analysis]
36 Liu YJ, Zhou Y, Yeh MM. Recurrent genetic alterations in hepatitis C-associated hepatocellular carcinoma detected by genomic microarray: a genetic, clinical and pathological correlation study. Mol Cytogenet. 2014;7:81. [PMID: 25469175 DOI: 10.1186/s13039-014-0081-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
37 Alameda JP, Fernández-Aceñero MJ, Moreno-Maldonado R, Navarro M, Quintana R, Page A, Ramírez A, Bravo A, Casanova ML. CYLD regulates keratinocyte differentiation and skin cancer progression in humans. Cell Death Dis 2011;2:e208. [PMID: 21900959 DOI: 10.1038/cddis.2011.82] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
38 Lin YF, Li LH, Lin CH, Tsou MH, Chuang MT, Wu KM, Liao TL, Li JC, Wang WJ, Tomita A, Tomita B, Huang SF, Tsai SF. Selective Retention of an Inactive Allele of the DKK2 Tumor Suppressor Gene in Hepatocellular Carcinoma. PLoS Genet 2016;12:e1006051. [PMID: 27203079 DOI: 10.1371/journal.pgen.1006051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Guo X, Yanna, Ma X, An J, Shang Y, Huang Q, Yang H, Chen Z, Xing J. A meta-analysis of array-CGH studies implicates antiviral immunity pathways in the development of hepatocellular carcinoma. PLoS One 2011;6:e28404. [PMID: 22174799 DOI: 10.1371/journal.pone.0028404] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
40 Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, Pascale RM. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 2006;1765:126-47. [PMID: 16216419 DOI: 10.1016/j.bbcan.2005.08.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 29] [Article Influence: 0.7] [Reference Citation Analysis]
41 You HL, Weng SW, Li SH, Wei YC, Sheu JJ, Chen CM, Huang WT. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma. Exp Mol Pathol. 2012;92:281-286. [PMID: 22366251 DOI: 10.1016/j.yexmp.2012.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
42 Blake PW, Toro JR. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat. 2009;30:1025-1036. [PMID: 19462465 DOI: 10.1002/humu.21024] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 5.6] [Reference Citation Analysis]
43 Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29-86. [PMID: 16095999 DOI: 10.1016/s0065-230x(05)94002-5] [Cited by in Crossref: 570] [Cited by in F6Publishing: 303] [Article Influence: 33.5] [Reference Citation Analysis]
44 Park SJ, Jeong SY, Kim HJ. Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array. Cancer Genet Cytogenet 2006;166:56-64. [PMID: 16616112 DOI: 10.1016/j.cancergencyto.2005.08.022] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
45 Jia X, Mo Z, Zhao Q, Bao T, Xu W, Gao Z, Peng L, Zhu X. Transcriptome alterations in HepG2 cells induced by shRNA knockdown and overexpression of TMEM2 gene. Biosci Biotechnol Biochem 2020;84:1576-84. [PMID: 32326855 DOI: 10.1080/09168451.2020.1756733] [Reference Citation Analysis]
46 Tsuji K, Kawauchi S, Saito S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, Hirano T, Sasaki K. Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer 2010;10:15. [PMID: 20070913 DOI: 10.1186/1471-2407-10-15] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
47 Gao Y, Yuan CY, Yuan W. Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies? Stem Cell Investig 2016;3:31. [PMID: 27583254 DOI: 10.21037/sci.2016.07.02] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
48 Chochi Y, Kawauchi S, Nakao M, Furuya T, Hashimoto K, Oga A, Oka M, Sasaki K. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol. 2009;217:677-684. [PMID: 19097070 DOI: 10.1002/path.2491] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
49 Sanches JGP, Xu Y, Yabasin IB, Li M, Lu Y, Xiu X, Wang L, Mao L, Shen J, Wang B, Hou L, Ju J, Zhao J, Song B. miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD. Chemico-Biological Interactions 2018;285:85-95. [DOI: 10.1016/j.cbi.2018.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
50 Kawaguchi K, Honda M, Yamashita T, Shirota Y, Kaneko S. Differential gene alteration among hepatoma cell lines demonstrated by cDNA microarray-based comparative genomic hybridization. Biochemical and Biophysical Research Communications 2005;329:370-80. [DOI: 10.1016/j.bbrc.2005.01.128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
51 Li Y, Xu A, Jia S, Huang J. Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. Oncol Lett 2019;17:4222-8. [PMID: 30988804 DOI: 10.3892/ol.2019.10127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
52 Rajasekaran D, Jariwala N, Mendoza RG, Robertson CL, Akiel MA, Dozmorov M, Fisher PB, Sarkar D. Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL). J Biol Chem 2016;291:10736-46. [PMID: 26997225 DOI: 10.1074/jbc.M116.715359] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
53 Wang Y, Zhou K, Wang X, Liu Y, Guo D, Bian Z, Su L, Liu K, Gu X, Guo X, Wang L, Zhang H, Tao K, Xing J. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments. Cancer Sci 2021. [PMID: 34490703 DOI: 10.1111/cas.15128] [Reference Citation Analysis]
54 Griffith DOL. Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers. Cancer Genetics 2022. [DOI: 10.1016/j.cancergen.2022.04.002] [Reference Citation Analysis]
55 Tian T, Bi H, Liu Y, Li G, Zhang Y, Cao L, Hu F, Zhao Y, Yuan H. Copy number variation of ubiquitin- specific proteases genes in blood leukocytes and colorectal cancer. Cancer Biol Ther 2020;21:637-46. [PMID: 32364424 DOI: 10.1080/15384047.2020.1750860] [Reference Citation Analysis]
56 Skawran B, Steinemann D, Becker T, Buurman R, Flik J, Wiese B, Flemming P, Kreipe H, Schlegelberger B, Wilkens L. Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Mod Pathol 2008;21:1479-89. [PMID: 18820673 DOI: 10.1038/modpathol.2008.147] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
57 Kawauchi S, Furuya T, Nakao M, Ikemoto K, Oga A, Sasaki K. A simple method for enhancing hybridization efficiency in chromosome and array comparative genomic hybridization. Biotech Histochem 2011;86:192-8. [PMID: 20233021 DOI: 10.3109/10520291003666781] [Reference Citation Analysis]
58 Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 2014;35:461-468. [PMID: 24104553 DOI: 10.1093/carcin/bgt335] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
59 Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z, Guo C, Liu Y, Chen Z, Wang X, Chen D, Wei H, Wang S. MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Lett. 2015;356:809-818. [PMID: 25449782 DOI: 10.1016/j.canlet.2014.10.041] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
60 Shi Q, Hoffman B, Liu Q. PI3K-Akt signaling pathway upregulates hepatitis C virus RNA translation through the activation of SREBPs. Virology. 2016;490:99-108. [PMID: 26855332 DOI: 10.1016/j.virol.2016.01.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
61 Restuccia DF, Hemmings BA. From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech 2010;3:705-20. [PMID: 20940316 DOI: 10.1242/dmm.004671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
62 Zhang B, Deng C, Wang L, Zhou F, Zhang S, Kang W, Zhan P, Chen J, Shen S, Guo H, Zhang M, Wang Y, Zhang F, Zhang W, Xiao J, Kong B, Friess H, Zhuge Y, Yan H, Zou X. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway. Mol Carcinog 2018;57:201-15. [PMID: 29027712 DOI: 10.1002/mc.22747] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
63 Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun. 2010;11:232-238. [PMID: 20237496 DOI: 10.1038/gene.2010.1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
64 Dolezal S, Hester S, Kirby PS, Nairn A, Pierce M, Abbott KL. Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by C. septicum alpha toxin. Cancer Biomark 2014;14:55-62. [PMID: 24643042 DOI: 10.3233/CBM-130377] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
65 Yasuda H, Nakagawa M, Kiyokawa H, Yoshida E, Yoshimura T, Koshikawa N, Itoh F, Seiki M. Unique Biological Activity and Potential Role of Monomeric Laminin-γ2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review. Int J Mol Sci 2019;20:E226. [PMID: 30626121 DOI: 10.3390/ijms20010226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
66 Ho JC, Cheung ST, Patil M, Chen X, Fan ST. Increased expression of glycosyl-phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma. Int J Cancer 2006;119:1330-7. [DOI: 10.1002/ijc.22005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
67 Ramakrishna G, Anwar T, Angara RK, Chatterjee N, Kiran S, Singh S. Role of cellular senescence in hepatic wound healing and carcinogenesis. Eur J Cell Biol 2012;91:739-47. [PMID: 22980320 DOI: 10.1016/j.ejcb.2012.08.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
68 Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007;133:1475-1486. [PMID: 17983802 DOI: 10.1053/j.gastro.2007.08.038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
69 Slany A, Haudek VJ, Zwickl H, Gundacker NC, Grusch M, Weiss TS, Seir K, Rodgarkia-Dara C, Hellerbrand C, Gerner C. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res 2010;9:6-21. [PMID: 19678649 DOI: 10.1021/pr900057t] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 5.6] [Reference Citation Analysis]
70 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.1] [Reference Citation Analysis]
71 Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T, Yamada-okabe H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol 2006;132:473-81. [DOI: 10.1007/s00432-006-0094-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
72 Kinoshita H, Okabe H, Beppu T, Chikamoto A, Hayashi H, Imai K, Mima K, Nakagawa S, Yokoyama N, Ishiko T, Shinriki S, Jono H, Ando Y, Baba H. CYLD downregulation is correlated with tumor development in patients with hepatocellular carcinoma. Mol Clin Oncol 2013;1:309-14. [PMID: 24649166 DOI: 10.3892/mco.2013.68] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
73 Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol. 2005;43:863-874. [PMID: 16139920 DOI: 10.1016/j.jhep.2005.05.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
74 Patil MA, Gütgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, Li R, Dykema KJ, So S, Fan ST. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis. 2005;26:2050-2057. [PMID: 16000397 DOI: 10.1093/carcin/bgi178] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 6.1] [Reference Citation Analysis]